Supreme Court to Hear Prometheus v. Mayo; Diagnostic Methods Case Could Have Broad PGx Impact | GenomeWeb

Originally published Jan. 21.

The US Supreme Court has agreed to hear a case that could ultimately have a broad impact on gene patenting and other intellectual property issues of interest to personalized medicine stakeholders.

The court on June 20 granted Mayo Medical Laboratories a writ of certiorari in its appeal of a lower court's decision that upheld two diagnostic method patents held by Prometheus Laboratories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.